Consensus ORIC Pharmaceuticals, Inc.

Stocks

ORIC

US68622P1093

Biotechnology & Medical Research

Market Closed - Nasdaq 06:00:00 23/09/26 am AEST			5-day change	1st Jan Change
13.50 ^USD	+6.55%		+9.22%	+65.04%

16/09	ORIC Pharmaceuticals, Inc. Presents at Morgan Stanley 24th Annual Global Healthcare Conference, Sep-15-2026 10:00 AM
29/08	Oric Pharmaceuticals Insider Sold Shares Worth $1,053,814, According to a Recent SEC Filing	MT

Evolution of the Average Target: ORIC Pharmaceuticals, Inc.

Evolution of the Target Price: ORIC Pharmaceuticals, Inc.

Changes in Analyst Recommendations: ORIC Pharmaceuticals, Inc.

41718d9f5529ff4.LiVzqv87qPueirEdvxfCvEk0xyTBm5ZQvsy_dX0Gqc8.SnJF_qZc257W8IUv7ECJ3TpsrxSrxNgc6a_QPhor_qBIdjfJi3jCycez-A~6ff147e74cf7910595228db113aab8f5

Analysts' recommendations: ORIC Pharmaceuticals, Inc.

01/04	Wedbush Cuts Price Target on ORIC Pharmaceuticals to $17 From $20, Keeps Outperform Rating	MT
07/01	Piper Sandler Initiates ORIC Pharmaceuticals Inc at Overweight With $22 Price Target	MT
15/11	Oppenheimer Adjusts Price Target on ORIC Pharmaceuticals to $15 From $12, Maintains Outperform Rating	MT
06/05/25	Oppenheimer Adjusts Price Target on ORIC Pharmaceuticals to $12 From $15, Maintains Outperform Rating	MT
31/10/24	JonesTrading Initiates ORIC Pharmaceuticals at Buy With $17 Price Target	MT
31/10/24	Wells Fargo Initiates ORIC Pharmaceuticals at Overweight With $20 Price Target	MT
06/09/24	Stifel Nicolaus Initiates Coverage on ORIC Pharmaceuticals With Buy Rating, $20 Price Target	MT
13/08/24	Oppenheimer Adjusts ORIC Pharmaceuticals Price Target to $15 From $17, Maintains Outperform Rating	MT
28/03/24	JPMorgan Trims ORIC Pharmaceuticals' Price Target to $18 From $19, Maintains Overweight Rating	MT
21/03/24	HC Wainwright Adjusts ORIC Pharmaceuticals' Price Target to $21 From $15, Keeps Buy Rating	MT
12/03/24	Baird Cuts Price Target on ORIC Pharmaceuticals to $25 From $27, Maintains Outperform Rating	MT
01/03/24	Wedbush Adjusts Oric Pharmaceuticals' Price Target to $20 From $12, Maintains Outperform Rating	MT
27/02/24	Cantor Fitzgerald Initiates ORIC Pharmaceuticals at Overweight Rating	MT
14/12/23	HC Wainwright Trims Price Target on ORIC Pharmaceuticals to $15 From $16, Keeps Buy Rating	MT
12/12/23	Wedbush Lowers ORIC Pharmaceuticals' PT to $12 From $14, Pushes Out Launch Assumption for ORIC-533; Keeps Outperform Rating	MT
26/10/23	HC Wainwright Adjusts Price Target on ORIC Pharmaceuticals to $16 From $13, Maintains Buy Rating	MT
25/10/23	JPMorgan Adjusts ORIC Pharmaceuticals' Price Target to $17 From $14, Maintains Overweight Rating	MT
24/10/23	Citigroup Adjusts ORIC Pharmaceuticals' Price Target to $15 From $13, Maintains Buy Rating	MT
22/09/23	Wedbush Starts ORIC Pharmaceuticals at Outperform With $14 PT, Says Expanding Pipeline Provides Future Potential Growth Opportunities	MT
16/08/23	Baird Adjusts Price Target on ORIC Pharmaceuticals to $27 From $15, Keeps Outperform Rating	MT
15/08/23	HC Wainwright Adjusts Price Target on ORIC Pharmaceuticals to $13 From $14, Keeps Buy Rating	MT
10/05/23	HC Wainwright Adjusts Price Target on ORIC Pharmaceuticals to $14 From $16, Keeps Buy Rating	MT
05/04/23	Citigroup Adjusts Price Target on ORIC Pharmaceuticals to $8 From $9, Maintains Buy Rating	MT
23/03/23	HC Wainwright Upgrades ORIC Pharmaceuticals to Buy From Neutral, Price Target is $16	MT
22/03/23	Guggenheim Upgrades ORIC Pharmaceuticals to Buy From Neutral, Price Target is $15	MT

More recommendations

Bio Therapeutic Drugs

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	ORIC PHARMACEUTICALS, INC.					+53.09%
	WUXI APPTEC CO., LTD.					+11.45%
	ARGENX SE					+20.14%
	WUXI BIOLOGICS (CAYMAN) INC.					+10.58%
	INSMED INCORPORATED					+65.16%
	BIONTECH SE					+17.73%
	GENMAB A/S					+1.06%
	SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.					+26.41%
	PHARMAESSENTIA CORPORATION					+20.45%
	EXELIXIS, INC.					-7.67%
	Average					+21.84%
	Weighted average by Cap.					+18.59%